Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Zenocutuzumab-zbco

Placeholder slot
 (ZEH-noh-kyoo-TOO-zyoo-mab)

This page contains brief information about zenocutuzumab-zbco and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Bizengri
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Zenocutuzumab-zbco is approved to treat adults with cancer that has an NRG1 gene fusion, has spread or cannot be removed by surgery, and has gotten worse during or after systemic therapy. Cancers treated with zenocutuzumab-zbco include:

¹These uses are approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that zenocutuzumab-zbco provides a clinical benefit in these patients.

Zenocutuzumab-zbco is also being studied in the treatment of other types of cancer.

More About Zenocutuzumab-zbco

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Zenocutuzumab-zbco - A lay language summary of important information about this drug.

Research Results and Related Resources

Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic Change

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Zenocutuzumab-zbco - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email